Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

NCT03746912 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia With Gene Mutations

Interventions

DRUG: Quizartinib Dihydrochloride

Sponsor

Daiichi Sankyo